Based on these promising evidences of ICI and KITi combination, we proposed to conduct the phase I/II clinical trial of imatinib mesylate (KITi) with pembrolizumab (anti-PD-1 antibody) for KIT-mutant melanoma patients who progressed after ICIs. Here, KIT is linked to melanoma.